The role and advances of immunomodulator therapy for inflammatory bowel disease

Research output: Contribution to journal › Review › Research › peer-review

Standard

The role and advances of immunomodulator therapy for inflammatory bowel disease. / Nielsen, Ole Haagen; Coskun, Mehmet; Steenholdt, Casper; Rogler, Gerhard.

In: Expert Review of Gastroenterology & Hepatology, Vol. 9, No. 2, 2015, p. 177-189.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Nielsen, OH, Coskun, M, Steenholdt, C & Rogler, G 2015, 'The role and advances of immunomodulator therapy for inflammatory bowel disease', Expert Review of Gastroenterology & Hepatology, vol. 9, no. 2, pp. 177-189. https://doi.org/10.1586/17474124.2014.945914

APA

Nielsen, O. H., Coskun, M., Steenholdt, C., & Rogler, G. (2015). The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology, 9(2), 177-189. https://doi.org/10.1586/17474124.2014.945914

Vancouver

Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. 2015;9(2):177-189. https://doi.org/10.1586/17474124.2014.945914

Author

Nielsen, Ole Haagen ; Coskun, Mehmet ; Steenholdt, Casper ; Rogler, Gerhard. / The role and advances of immunomodulator therapy for inflammatory bowel disease. In: Expert Review of Gastroenterology & Hepatology. 2015 ; Vol. 9, No. 2. pp. 177-189.

Bibtex

@article{b2b456540138498e8bde99134906459b,
title = "The role and advances of immunomodulator therapy for inflammatory bowel disease",
abstract = "Immune modulating drugs such as thiopurines (azathioprine and 6-mercaptopurine) and methotrexate has been a mainstay for treatment of inflammatory bowel disease (IBD) for decades. However, despite widely used in IBD, questions still remain concerning the most rational treatment regimens of these agents. Results from a range of recent studies necessitate increased awareness on how to best use these potent drugs in the clinic. As controversy still remains regarding the most appropriate use of immunomodulators, this review is based on scrutinizing the current literature, with emphasis on randomized controlled trials and Cochrane reviews, focusing on aspects that can lead to optimal and evidence-based thiopurine and methotrexate treatment strategies in IBD.",
keywords = "6-Mercaptopurine, Azathioprine, Humans, Immunologic Factors, Immunomodulation, Inflammatory Bowel Diseases, Methotrexate, Treatment Outcome",
author = "Nielsen, {Ole Haagen} and Mehmet Coskun and Casper Steenholdt and Gerhard Rogler",
year = "2015",
doi = "10.1586/17474124.2014.945914",
language = "English",
volume = "9",
pages = "177--189",
journal = "Expert Review of Gastroenterology & Hepatology",
issn = "1747-4124",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - The role and advances of immunomodulator therapy for inflammatory bowel disease

AU - Nielsen, Ole Haagen

AU - Coskun, Mehmet

AU - Steenholdt, Casper

AU - Rogler, Gerhard

PY - 2015

Y1 - 2015

N2 - Immune modulating drugs such as thiopurines (azathioprine and 6-mercaptopurine) and methotrexate has been a mainstay for treatment of inflammatory bowel disease (IBD) for decades. However, despite widely used in IBD, questions still remain concerning the most rational treatment regimens of these agents. Results from a range of recent studies necessitate increased awareness on how to best use these potent drugs in the clinic. As controversy still remains regarding the most appropriate use of immunomodulators, this review is based on scrutinizing the current literature, with emphasis on randomized controlled trials and Cochrane reviews, focusing on aspects that can lead to optimal and evidence-based thiopurine and methotrexate treatment strategies in IBD.

AB - Immune modulating drugs such as thiopurines (azathioprine and 6-mercaptopurine) and methotrexate has been a mainstay for treatment of inflammatory bowel disease (IBD) for decades. However, despite widely used in IBD, questions still remain concerning the most rational treatment regimens of these agents. Results from a range of recent studies necessitate increased awareness on how to best use these potent drugs in the clinic. As controversy still remains regarding the most appropriate use of immunomodulators, this review is based on scrutinizing the current literature, with emphasis on randomized controlled trials and Cochrane reviews, focusing on aspects that can lead to optimal and evidence-based thiopurine and methotrexate treatment strategies in IBD.

KW - 6-Mercaptopurine

KW - Azathioprine

KW - Humans

KW - Immunologic Factors

KW - Immunomodulation

KW - Inflammatory Bowel Diseases

KW - Methotrexate

KW - Treatment Outcome

U2 - 10.1586/17474124.2014.945914

DO - 10.1586/17474124.2014.945914

M3 - Review

C2 - 25101818

VL - 9

SP - 177

EP - 189

JO - Expert Review of Gastroenterology & Hepatology

JF - Expert Review of Gastroenterology & Hepatology

SN - 1747-4124

IS - 2

ER -

ID: 152248146